For Sun Pharma, its investment in speciality business is paying off, as it is becoming a driver of growth for the company’s US business. Cipla’s ‘One India’ strategy, focusing on branded prescription, trade generics and consumer health brands, is leading to continued core portfolio momentum across businesses.
10 stks that got upgrades & downgrades from MOSL post Q4 results
As all major companies have already announced their Q4 results, brokerage firm Motilal Oswal has upgraded and downgraded the estimated FY24 earnings of several stocks.